Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 185

1.

Anti-tumor activity and tolerability of hu14.18-IL2 with GMCSF and isotretinoin in recurrent or refractory neuroblastoma: A Children's Oncology Group phase II study.

Shusterman S, Naranjo A, Van Ryn C, Hank JA, Parisi MT, Shulkin BL, London WB, Shimada H, Gan J, Gillies SD, Maris JM, Park JR, Sondel PM, Servaes S.

Clin Cancer Res. 2019 Jul 29. pii: clincanres.0798.2019. doi: 10.1158/1078-0432.CCR-19-0798. [Epub ahead of print]

PMID:
31358541
2.

Human and murine IL2 receptors differentially respond to the human-IL2 component of immunocytokines.

Perez Horta Z, Saseedhar S, Rakhmilevich AL, Carmichael L, Hank JA, Boyden M, Gillies SD, Sondel PM.

Oncoimmunology. 2018 May 7;8(6):e1238538. doi: 10.1080/2162402X.2016.1238538. eCollection 2019.

3.

Evaluating natural killer cell cytotoxicity against solid tumors using a microfluidic model.

Ayuso JM, Truttschel R, Gong MM, Humayun M, Virumbrales-Munoz M, Vitek R, Felder M, Gillies SD, Sondel P, Wisinski KB, Patankar M, Beebe DJ, Skala MC.

Oncoimmunology. 2018 Dec 12;8(3):1553477. doi: 10.1080/2162402X.2018.1553477. eCollection 2019.

PMID:
30723584
4.

MUC16 suppresses human and murine innate immune responses.

Felder M, Kapur A, Rakhmilevich AL, Qu X, Sondel PM, Gillies SD, Connor J, Patankar MS.

Gynecol Oncol. 2019 Mar;152(3):618-628. doi: 10.1016/j.ygyno.2018.12.023. Epub 2019 Jan 6.

PMID:
30626487
5.

Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma.

Albertini MR, Yang RK, Ranheim EA, Hank JA, Zuleger CL, Weber S, Neuman H, Hartig G, Weigel T, Mahvi D, Henry MB, Quale R, McFarland T, Gan J, Carmichael L, Kim K, Loibner H, Gillies SD, Sondel PM.

Cancer Immunol Immunother. 2018 Oct;67(10):1647-1658. doi: 10.1007/s00262-018-2223-z. Epub 2018 Aug 3.

PMID:
30073390
6.

Tumor-Specific Inhibition of In Situ Vaccination by Distant Untreated Tumor Sites.

Morris ZS, Guy EI, Werner LR, Carlson PM, Heinze CM, Kler JS, Busche SM, Jaquish AA, Sriramaneni RN, Carmichael LL, Loibner H, Gillies SD, Korman AJ, Erbe AK, Hank JA, Rakhmilevich AL, Harari PM, Sondel PM.

Cancer Immunol Res. 2018 Jul;6(7):825-834. doi: 10.1158/2326-6066.CIR-17-0353. Epub 2018 May 10.

7.

Adoption of in vitro systems and zebrafish embryos as alternative models for reducing rodent use in assessments of immunological and oxidative stress responses to nanomaterials.

Johnston HJ, Verdon R, Gillies S, Brown DM, Fernandes TF, Henry TB, Rossi AG, Tran L, Tucker C, Tyler CR, Stone V.

Crit Rev Toxicol. 2018 Mar;48(3):252-271. doi: 10.1080/10408444.2017.1404965. Epub 2017 Dec 14. Review.

8.

A founder mutation in CERKL is a major cause of retinal dystrophy in Finland.

Avela K, Sankila EM, Seitsonen S, Kuuluvainen L, Barton S, Gillies S, Aittomäki K.

Acta Ophthalmol. 2018 Mar;96(2):183-191. doi: 10.1111/aos.13551. Epub 2017 Oct 25.

9.

Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group.

Erbe AK, Wang W, Carmichael L, Kim K, Mendonça EA, Song Y, Hess D, Reville PK, London WB, Naranjo A, Hank JA, Diccianni MB, Reisfeld RA, Gillies SD, Matthay KK, Cohn SL, Hogarty MD, Maris JM, Park JR, Ozkaynak MF, Gilman AL, Yu AL, Sondel PM.

Clin Cancer Res. 2018 Jan 1;24(1):189-196. doi: 10.1158/1078-0432.CCR-17-1767. Epub 2017 Oct 2.

10.

Tumor-targeted IL-12 combined with local irradiation leads to systemic tumor control via abscopal effects in vivo.

Eckert F, Jelas I, Oehme M, Huber SM, Sonntag K, Welker C, Gillies SD, Strittmatter W, Zips D, Handgretinger R, Schilbach K.

Oncoimmunology. 2017 Apr 28;6(6):e1323161. doi: 10.1080/2162402X.2017.1323161. eCollection 2017.

11.

Effective Combination of Innate and Adaptive Immunotherapeutic Approaches in a Mouse Melanoma Model.

Rakhmilevich AL, Felder M, Lever L, Slowinski J, Rasmussen K, Hoefges A, Van De Voort TJ, Loibner H, Korman AJ, Gillies SD, Sondel PM.

J Immunol. 2017 Feb 15;198(4):1575-1584. doi: 10.4049/jimmunol.1601255. Epub 2017 Jan 6.

12.

Enhanced binding of necrosis-targeting immunocytokine NHS-IL12 after local tumour irradiation in murine xenograft models.

Eckert F, Schmitt J, Zips D, Krueger MA, Pichler BJ, Gillies SD, Strittmatter W, Handgretinger R, Schilbach K.

Cancer Immunol Immunother. 2016 Aug;65(8):1003-13. doi: 10.1007/s00262-016-1863-0. Epub 2016 Jul 4.

PMID:
27376889
13.

In Situ Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments.

Morris ZS, Guy EI, Francis DM, Gressett MM, Werner LR, Carmichael LL, Yang RK, Armstrong EA, Huang S, Navid F, Gillies SD, Korman A, Hank JA, Rakhmilevich AL, Harari PM, Sondel PM.

Cancer Res. 2016 Jul 1;76(13):3929-41. doi: 10.1158/0008-5472.CAN-15-2644. Epub 2016 May 6.

14.

Cancer-targeted IL-12 controls human rhabdomyosarcoma by senescence induction and myogenic differentiation.

Schilbach K, Alkhaled M, Welker C, Eckert F, Blank G, Ziegler H, Sterk M, Müller F, Sonntag K, Wieder T, Braumüller H, Schmitt J, Eyrich M, Schleicher S, Seitz C, Erbacher A, Pichler BJ, Müller H, Tighe R, Lim A, Gillies SD, Strittmatter W, Röcken M, Handgretinger R.

Oncoimmunology. 2015 Mar 19;4(7):e1014760. eCollection 2015 Jul.

15.

Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma.

Navid F, Sondel PM, Barfield R, Shulkin BL, Kaufman RA, Allay JA, Gan J, Hutson P, Seo S, Kim K, Goldberg J, Hank JA, Billups CA, Wu J, Furman WL, McGregor LM, Otto M, Gillies SD, Handgretinger R, Santana VM.

J Clin Oncol. 2014 May 10;32(14):1445-52. doi: 10.1200/JCO.2013.50.4423. Epub 2014 Apr 7.

16.

A new platform for constructing antibody-cytokine fusion proteins (immunocytokines) with improved biological properties and adaptable cytokine activity.

Gillies SD.

Protein Eng Des Sel. 2013 Oct;26(10):561-9. doi: 10.1093/protein/gzt045. Epub 2013 Sep 10.

PMID:
24025193
17.

Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival.

Yang RK, Kalogriopoulos NA, Rakhmilevich AL, Ranheim EA, Seo S, Kim K, Alderson KL, Gan J, Reisfeld RA, Gillies SD, Hank JA, Sondel PM.

Cancer Immunol Immunother. 2013 Aug;62(8):1303-13. doi: 10.1007/s00262-013-1430-x. Epub 2013 May 10.

18.

Nondisjunctional segregations in Drosophila female meiosis I are preceded by homolog malorientation at metaphase arrest.

Gillies SC, Lane FM, Paik W, Pyrtel K, Wallace NT, Gilliland WD.

Genetics. 2013 Feb;193(2):443-51. doi: 10.1534/genetics.112.146241. Epub 2012 Dec 5.

19.

Enhancement of the anti-melanoma response of Hu14.18K322A by αCD40 + CpG.

Alderson KL, Luangrath M, Elsenheimer MM, Gillies SD, Navid F, Rakhmilevich AL, Sondel PM.

Cancer Immunol Immunother. 2013 Apr;62(4):665-75. doi: 10.1007/s00262-012-1372-8. Epub 2012 Nov 15.

20.

Intratumoral hu14.18-IL-2 (IC) induces local and systemic antitumor effects that involve both activated T and NK cells as well as enhanced IC retention.

Yang RK, Kalogriopoulos NA, Rakhmilevich AL, Ranheim EA, Seo S, Kim K, Alderson KL, Gan J, Reisfeld RA, Gillies SD, Hank JA, Sondel PM.

J Immunol. 2012 Sep 1;189(5):2656-64. doi: 10.4049/jimmunol.1200934. Epub 2012 Jul 27.

21.

Current and Potential Uses of Immunocytokines as Cancer Immunotherapy.

Sondel PM, Gillies SD.

Antibodies (Basel). 2012 Jul 4;1(2):149-171.

22.

Phase II trial of hu14.18-IL2 for patients with metastatic melanoma.

Albertini MR, Hank JA, Gadbaw B, Kostlevy J, Haldeman J, Schalch H, Gan J, Kim K, Eickhoff J, Gillies SD, Sondel PM.

Cancer Immunol Immunother. 2012 Dec;61(12):2261-71. doi: 10.1007/s00262-012-1286-5. Epub 2012 Jun 8.

23.

Gene expression in the developing aleurone and starchy endosperm of wheat.

Gillies SA, Futardo A, Henry RJ.

Plant Biotechnol J. 2012 Aug;10(6):668-79. doi: 10.1111/j.1467-7652.2012.00705.x. Epub 2012 Jun 5.

24.

Anti-tumor and immunomodulatory activity of resveratrol in vitro and its potential for combining with cancer immunotherapy.

Soto BL, Hank JA, Darjatmoko SR, Polans AS, Yanke EM, Rakhmilevich AL, Seo S, Kim K, Reisfeld RA, Gillies SD, Sondel PM.

Int Immunopharmacol. 2011 Nov;11(11):1877-86. doi: 10.1016/j.intimp.2011.07.019. Epub 2011 Aug 18.

25.

Ab-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface.

Gubbels JA, Gadbaw B, Buhtoiarov IN, Horibata S, Kapur AK, Patel D, Hank JA, Gillies SD, Sondel PM, Patankar MS, Connor J.

Cancer Immunol Immunother. 2011 Dec;60(12):1789-800. doi: 10.1007/s00262-011-1072-9. Epub 2011 Jul 27.

26.

NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin.

Esser R, Müller T, Stefes D, Kloess S, Seidel D, Gillies SD, Aperlo-Iffland C, Huston JS, Uherek C, Schönfeld K, Tonn T, Huebener N, Lode HN, Koehl U, Wels WS.

J Cell Mol Med. 2012 Mar;16(3):569-81. doi: 10.1111/j.1582-4934.2011.01343.x.

27.

A low-toxicity IL-2-based immunocytokine retains antitumor activity despite its high degree of IL-2 receptor selectivity.

Gillies SD, Lan Y, Hettmann T, Brunkhorst B, Sun Y, Mueller SO, Lo KM.

Clin Cancer Res. 2011 Jun 1;17(11):3673-85. doi: 10.1158/1078-0432.CCR-10-2921. Epub 2011 Apr 29.

28.

The anti-tumor effect of resveratrol alone or in combination with immunotherapy in a neuroblastoma model.

Soto BL, Hank JA, Van De Voort TJ, Subramanian L, Polans AS, Rakhmilevich AL, Yang RK, Seo S, Kim K, Reisfeld RA, Gillies SD, Sondel PM.

Cancer Immunol Immunother. 2011 May;60(5):731-8. doi: 10.1007/s00262-011-0971-0. Epub 2011 Feb 22.

29.

Differential internalization of hu14.18-IL2 immunocytokine by NK and tumor cell: impact on conjugation, cytotoxicity, and targeting.

Buhtoiarov IN, Neal ZC, Gan J, Buhtoiarova TN, Patankar MS, Gubbels JA, Hank JA, Yamane B, Rakhmilevich AL, Reisfeld RA, Gillies SD, Sondel PM.

J Leukoc Biol. 2011 Apr;89(4):625-38. doi: 10.1189/jlb.0710422. Epub 2011 Jan 19.

30.

Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy.

Delgado DC, Hank JA, Kolesar J, Lorentzen D, Gan J, Seo S, Kim K, Shusterman S, Gillies SD, Reisfeld RA, Yang R, Gadbaw B, DeSantes KB, London WB, Seeger RC, Maris JM, Sondel PM.

Cancer Res. 2010 Dec 1;70(23):9554-61. doi: 10.1158/0008-5472.CAN-10-2211. Epub 2010 Oct 8.

31.

Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study.

Shusterman S, London WB, Gillies SD, Hank JA, Voss SD, Seeger RC, Reynolds CP, Kimball J, Albertini MR, Wagner B, Gan J, Eickhoff J, DeSantes KB, Cohn SL, Hecht T, Gadbaw B, Reisfeld RA, Maris JM, Sondel PM.

J Clin Oncol. 2010 Nov 20;28(33):4969-75. doi: 10.1200/JCO.2009.27.8861. Epub 2010 Oct 4.

32.

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.

Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM; Children's Oncology Group.

N Engl J Med. 2010 Sep 30;363(14):1324-34. doi: 10.1056/NEJMoa0911123.

33.

Distinct gene expression profiles directed by the isoforms of the transcription factor neuron-restrictive silencer factor in human SK-N-AS neuroblastoma cells.

Gillies SG, Haddley K, Vasiliou SA, Jacobson GM, von Mentzer B, Bubb VJ, Quinn JP.

J Mol Neurosci. 2011 Jun;44(2):77-90. doi: 10.1007/s12031-010-9420-3. Epub 2010 Jul 23.

PMID:
20652837
34.

Anti-GD(2) with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia.

Sorkin LS, Otto M, Baldwin WM 3rd, Vail E, Gillies SD, Handgretinger R, Barfield RC, Ming Yu H, Yu AL.

Pain. 2010 Apr;149(1):135-42. doi: 10.1016/j.pain.2010.01.024. Epub 2010 Feb 19.

35.

Word of mouth in the digital age: online physician ratings.

Gillies S; KarenZupko & Associates, Inc.

Am J Orthop (Belle Mead NJ). 2009 Aug;38(8):417-9. No abstract available.

PMID:
19809607
36.

Immunogenicity of the hu14.18-IL2 immunocytokine molecule in adults with melanoma and children with neuroblastoma.

Hank JA, Gan J, Ryu H, Ostendorf A, Stauder MC, Sternberg A, Albertini M, Lo KM, Gillies SD, Eickhoff J, Sondel PM.

Clin Cancer Res. 2009 Sep 15;15(18):5923-30. doi: 10.1158/1078-0432.CCR-08-2963. Epub 2009 Sep 8.

37.

Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma.

Ribas A, Kirkwood JM, Atkins MB, Whiteside TL, Gooding W, Kovar A, Gillies SD, Kashala O, Morse MA.

J Transl Med. 2009 Jul 29;7:68. doi: 10.1186/1479-5876-7-68.

38.

Radiofrequency ablation combined with KS-IL2 immunocytokine (EMD 273066) results in an enhanced antitumor effect against murine colon adenocarcinoma.

Johnson EE, Yamane BH, Buhtoiarov IN, Lum HD, Rakhmilevich AL, Mahvi DM, Gillies SD, Sondel PM.

Clin Cancer Res. 2009 Aug 1;15(15):4875-84. doi: 10.1158/1078-0432.CCR-09-0110. Epub 2009 Jul 28.

39.

The human neurokinin B gene, TAC3, and its promoter are regulated by Neuron Restrictive Silencing Factor (NRSF) transcription factor family.

Gillies S, Haddley K, Vasiliou S, Bubb VJ, Quinn JP.

Neuropeptides. 2009 Aug;43(4):333-40. doi: 10.1016/j.npep.2009.05.004. Epub 2009 Jun 17.

PMID:
19539370
40.

Keeping your money safe: cash controls and security for physician practices.

Gillies S.

Am J Orthop (Belle Mead NJ). 2009 Jan;38(1):42-4. No abstract available.

PMID:
19238267
41.

Disaster preparedness--don't get caught without a plan.

Gillies S, Zupko K.

Am J Orthop (Belle Mead NJ). 2008 Dec;37(12):632-5. No abstract available.

PMID:
19212574
42.

Inactivation of an aminoaldehyde dehydrogenase is responsible for fragrance in rice.

Bradbury LM, Gillies SA, Brushett DJ, Waters DL, Henry RJ.

Plant Mol Biol. 2008 Nov;68(4-5):439-49. doi: 10.1007/s11103-008-9381-x. Epub 2008 Aug 13.

PMID:
18704694
43.

Intratumoral immunocytokine treatment results in enhanced antitumor effects.

Johnson EE, Lum HD, Rakhmilevich AL, Schmidt BE, Furlong M, Buhtoiarov IN, Hank JA, Raubitschek A, Colcher D, Reisfeld RA, Gillies SD, Sondel PM.

Cancer Immunol Immunother. 2008 Dec;57(12):1891-902. doi: 10.1007/s00262-008-0519-0. Epub 2008 Apr 26.

44.

Linking antibody Fc domain to endostatin significantly improves endostatin half-life and efficacy.

Lee TY, Tjin Tham Sjin RM, Movahedi S, Ahmed B, Pravda EA, Lo KM, Gillies SD, Folkman J, Javaherian K.

Clin Cancer Res. 2008 Mar 1;14(5):1487-93. doi: 10.1158/1078-0432.CCR-07-1530.

45.

Positron emission tomography (PET) imaging of neuroblastoma and melanoma with 64Cu-SarAr immunoconjugates.

Voss SD, Smith SV, DiBartolo N, McIntosh LJ, Cyr EM, Bonab AA, Dearling JL, Carter EA, Fischman AJ, Treves ST, Gillies SD, Sargeson AM, Huston JS, Packard AB.

Proc Natl Acad Sci U S A. 2007 Oct 30;104(44):17489-93. Epub 2007 Oct 22.

46.

Caspase-8-mediated apoptosis induced by oxidative stress is independent of the intrinsic pathway and dependent on cathepsins.

Baumgartner HK, Gerasimenko JV, Thorne C, Ashurst LH, Barrow SL, Chvanov MA, Gillies S, Criddle DN, Tepikin AV, Petersen OH, Sutton R, Watson AJ, Gerasimenko OV.

Am J Physiol Gastrointest Liver Physiol. 2007 Jul;293(1):G296-307. Epub 2007 Apr 12.

47.

Flt3-L gene therapy enhances immunocytokine-mediated antitumor effects and induces long-term memory.

Neal ZC, Sondel PM, Bates MK, Gillies SD, Herweijer H.

Cancer Immunol Immunother. 2007 Nov;56(11):1765-74. Epub 2007 Apr 11.

PMID:
17426968
48.

Combining adoptive cellular and immunocytokine therapies to improve treatment of B-lineage malignancy.

Singh H, Serrano LM, Pfeiffer T, Olivares S, McNamara G, Smith DD, Al-Kadhimi Z, Forman SJ, Gillies SD, Jensen MC, Colcher D, Raubitschek A, Cooper LJ.

Cancer Res. 2007 Mar 15;67(6):2872-80.

49.

Menadione-induced reactive oxygen species generation via redox cycling promotes apoptosis of murine pancreatic acinar cells.

Criddle DN, Gillies S, Baumgartner-Wilson HK, Jaffar M, Chinje EC, Passmore S, Chvanov M, Barrow S, Gerasimenko OV, Tepikin AV, Sutton R, Petersen OH.

J Biol Chem. 2006 Dec 29;281(52):40485-92. Epub 2006 Nov 6.

50.

huBC1-IL12, an immunocytokine which targets EDB-containing oncofetal fibronectin in tumors and tumor vasculature, shows potent anti-tumor activity in human tumor models.

Lo KM, Lan Y, Lauder S, Zhang J, Brunkhorst B, Qin G, Verma R, Courtenay-Luck N, Gillies SD.

Cancer Immunol Immunother. 2007 Apr;56(4):447-57. Epub 2006 Jul 28.

PMID:
16874486

Supplemental Content

Loading ...
Support Center